No Data
No Data
Alzamend Neuro To Present Non-Clinical Data Update On Pharmacokinetics Of AL001, A Lithium Salicylate/L-Proline Co-crystal, As A Potentially Beneficial Lithium Sparing Treatment For Bipolar Disorder Type 1, Alzheimer's Disease, Major Depressive...
Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo
Express News | Ascendiant Capital Maintains Buy on Alzamend Neuro, Lowers Price Target to $32
Alzamend Neuro | 8-K: Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs
Alzamend Neuro Says Net Cash Gained by Financing Activity $8.3M
Express News | Alzamend Neuro Q2 EPS $(0.40) Beats $(0.77) Estimate
Unlock the Full List